Close menu

November 24th, 2021 | 12:41 CET

BioNTech, Defence Therapeutics, Novavax: Another step towards vaccination against cancer

  • Biotechnology
Photo credits:

In Portugal and Spain, vaccination rates are higher than in Germany. There are various discussions about the reasons for this. One argument is the fact that infant mortality was high in both countries for a long time. Those who still vividly remember the stories of dead or lifelong damaged infants are less likely to think twice when the doctor calls for vaccination. The recent experience with BioNTech and other vaccines could also give a new boost to the willingness to vaccinate. It is, therefore, quite fitting that vaccines against many different diseases are now emerging on the market.

time to read: 3 minutes | Author: Nico Popp

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    BioNTech: One success story

    Before the vaccine champions at BioNTech announced their decision to develop a vaccine against COVID-19 early in 2020, mRNA technology focused on other uses. Among them, the fight against cancer. BioNTech had previously been researching and developing for years and was capitalizing on the pandemic. Suddenly, approval procedures and the bureaucracy behind them no longer seemed to be an obstacle. Also, the US government emphasized that a vaccine could cost whatever it wanted. These conditions ensured that vaccine developers could focus on the essentials - and go all out without risk.

    Whereas a mistake in developing a vaccine or drug without regular evaluation can be costly, this risk was largely eliminated in the case of the vaccine developed by BioNTech and Pfizer. The results were impressive. The two pharmaceutical specialists moved forward with clinical trials at lightning speed, and the results surprised everyone: an efficacy rate of over 90% was far more than many observers had expected. The fact that the effect wears off over time and that BioNTech, like many other vaccines, probably has to be vaccinated in a triple schedule is something we have only known since the summer. That does not diminish the success of BioNTech. The booster wave is bringing fresh capital into the Company's coffers. At the same time, BioNTech is likely to have new versions of its vaccine already up its sleeve to make adjustments in the next variant. Keeping these aces up its sleeve makes perfect sense - after all, the virus is also adjusting to the conditions. BioNTech is a world-class company, but it is now also expensive.

    Defence Therapeutics: Focus on breast and skin cancer

    The example of Defence Therapeutics shows that it sometimes makes perfect sense to think outside the box when making investments. With Accum™, the Company has developed a technology that enables antibodies to piggyback on certain active ingredients and transport them exactly where they are needed. These so-called Antibody Drug Conjugates (ADCs), i.e. the combination of antibody and active ingredient, are often cited in the research community as a great source of hope. Since these ADCs are also ideally suited for use in vaccines, Defence Therapeutics is also pursuing an ambitious vaccine development program with its sights set on nothing less than the fight against cancer.

    Most recently, the Company announced that it has entered into an agreement with the Lady Davis Institute Cell Processing Center (CPC) to produce the vaccine candidate AccuVAC-D001. The focus of the vaccine is to fight melanoma, or skin cancer, and breast cancer. Both types of cancer are highly prevalent - almost everyone will have heard of such diseases in their family or acquaintances. The agreement now concluded is an important step towards the complete evaluation and ultimately the vaccine's approval following the completion of successful studies. "By entering into this agreement, we have taken another step towards initiating our Phase I trial with our proprietary AccumTM DC technology. These trials will not only establish the "blueprints" for our manufacturing process but also implement key quality control steps required by regulatory authorities before we can begin treating melanoma and breast cancer patients in 2022," Mr. Plouffe, CEO of Defence Therapeutics, said in a press release. Shares of Defence Therapeutics have been in a slight downward consolidation over the past three months but have already reacted positively to the news. In German trading, the stock could pick up additional momentum beyond EUR 4.50. However, investors should bear in mind that the value is speculative due to the pending approval procedure. However, the technology is certainly promising for the future!

    Novavax: There is life in the old dog yet

    Novavax shows that even old technology can have a future. The vaccine manufacturer wants to score points with a dead vaccine against COVID-19. The vaccinees are injected with an inactive virus - this method has been tried and tested for decades. It is therefore also the preferred choice of skeptical people, such as soccer player Joshua Kimmich. Although in the broadest sense, Moderna and BioNTech's mRNA technology also relies on dead vaccines, Novovax's solution could still appeal to new vaccinees, helping to close vaccination gaps and finally defeat the pandemic. Novavax's vaccine could be approved in the EU in as little as a few weeks.

    The share price has already risen by around 60% in the past four weeks. Defence Therapeutics currently offers greater potential. Although COVID-19 is not involved here, vaccines against common types of cancer are likely to trigger a run similar to the one that once took place in BioNTech shares. The latter rose by a whopping 226% last year alone. It may therefore be worthwhile for investors to think a little outside the box.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?


    Commented by Fabian Lorenz on April 10th, 2024 | 07:00 CEST

    BASF and Cardiol Therapeutics recommended to buy! TUI share with momentum!

    • Biotechnology
    • Cancer
    • travel
    • chemicals

    BASF shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the share did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases. The situation is different for the biotech company Cardiol Therapeutics. The analysts at Canaccord believe that the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter. The TUI share has been on a roll for several months now. Will the share continue to rise with the increase in temperatures? Management is certainly optimistic about the future.


    Commented by André Will-Laudien on April 10th, 2024 | 06:45 CEST

    Attention: Biotech takeovers, after MorphoSys, now Bayer, Vidac Pharma, BioNTech and Pfizer are on the radar

    • Pharma
    • Biotechnology
    • Innovations

    Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the cancer specialist from Munich. Only months before, MorphoSys had been traded on the stock exchange at just EUR 700 million. The special market situation in this case was also characterized by the high short ratio, which led to an exorbitant rise in the share price of almost 400% in the final phase. Speculative investors are now keeping a wary eye on potential takeover candidates as the sector is once again attracting considerable attention. We are taking a closer look and searching for the next pearl.